Implanted Ports versus Peripheral Collection: A Comparison of Methods for Therapeutic Antibiotic Level Monitoring in Pediatric Patients with Cystic Fibrosis
Emerging Knowledge for Clinical Practice Podium Presentations focusing on the Research Agenda Priority of Pediatric Research: Chronic Illness, Presented at NAPNAP's 40th National Conference on Pediatric Health Care, March 8, 2019, New Orleans, LA.
Authors: Maiuri L, Raia V, Piacentini M, Tosco A, Villella VR, Kroemer G Abstract Cystic Fibrosis (CF) is the most frequent lethal monogenetic disease affecting humans. CF is characterized by mutations in cystic fibrosis transmembrane conductance regulator (CFTR), a chloride channel whose malfunction triggers the activation of transglutaminase-2 (TGM2), as well as the inactivation of the Beclin-1 (BECN1) complex resulting in disabled autophagy. CFTR inhibition, TGM2 activation and BECN1 sequestration engage in an 'infernal trio' that locks the cell in a pro-inflammatory state through anti-homeostatic feedforward lo...
Condition: Confirmed Diagnosis of Cystic Fibrosis Intervention: Other: no intervention Sponsors: University Hospital Inselspital, Berne; University Children's Hospital, Zurich; Centre Hospitalier Universitaire Vaudois; Kantonsspital Aarau; University Children's Hospital Basel Recruiting
SAN JOSE, Calif., July 19, 2019 -- (Healthcare Sales &Marketing Network) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation to AR-501, the Company's inhaled formulat... Biopharmaceuticals, Regulatory Aridis Pharmaceuticals, gallium citrate, cystic fibrosis
FRIDAY, July 19, 2019 -- For patients with cystic fibrosis (CF), ivacaftor use is associated with a reduction in pathogens, including Pseudomonas aeruginosa, according to a study published online July 19 in the Annals of the American Thoracic...
5T polymorphism is a CFTR mutation with unclear clinical consequences: the phenotype varies from healthy individuals to Cystic Fibrosis (CF). The aim of this study was to evaluate if nasal potential difference (NPD) and sweat testing correlate with symptoms and CF diagnosis in 5T patients.
Notice NOT-DK-19-023 from the NIH Guide for Grants and Contracts
Conditions: Cystic Fibrosis; Nontuberculous Mycobacterium Infection Intervention: Other: Epidemiologic investigation Sponsors: National Jewish Health; Cystic Fibrosis Foundation Recruiting
We examined the safety and efficacy of aerosolized xylitol use for 2 weeks in subjects hospitalized with a pulmonary exacerbation of CF.